Avantium appoints bioplastics specialist

Jeffrey Kolstad joins as chief scientist from NatureWorks

Jeffrey Kolstad has joined Avantium as chief scientist, strengthening the Dutch firm’s team in developing next-generation bioplastics using its YXY technology.

Previously chief scientist at NatureWorks (formerly Cargill-Dow), Kolstad was one of the founding members of the team that developed and commercialised PLA (polylactic-acid), a bio-based polymer. He was also responsible for managing NatureWorks’ IP portfolio and strategy.

Prior to this Kolstad worked in the corporate research centres at Cargill and Amoco Oil Company.

You may also like

Research & Development

Avantium spins out pharma business

To create an independent business called Crystallics, specialising in solid state research
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
Manufacturing

Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters

Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258

The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
Subscribe now